Urolithin A
Mitochondrial SupportPreclinicalAlso known as: Mitopure, UA, Ellagitannin metabolite, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one, Urolithin
Urolithin A (3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one; trade name Mitopure from Timeline Nutrition, formerly Amazentis) is a gut-microbiome-derived metabolite of dietary ellagitannins — polyphenolic compounds found in pomegranates, walnuts, strawberries, raspberries, and several other berries. Unlike most dietary polyphenols, ellagitannins themselves are poorly absorbed from the intestine; their health-relevant bioactivity depends on conversion by specific gut bacteria (primarily Gordonibacter species, along with some Lactobacillus and Bifidobacterium strains) into a family of smaller metabolites called urolithins, of which urolithin A is the most biologically active.
Overview
At A Glance
Urolithin A's mechanism of action centers on induction of mitophagy — the selective autophagic degradation of damaged mitochondria — with additional secondary effects on mitochondrial biogenesis, cellular stress resistance, and inflammatory signaling. Understanding the mechanism …
Mechanism of Action
Urolithin A's mechanism of action centers on induction of mitophagy — the selective autophagic degradation of damaged mitochondria — with additional secondary effects on mitochondrial biogenesis, cellular stress resistance, and inflammatory signaling. Understanding the mechanism in detail clarifies why urolithin A complements rather than duplicates other mitochondrial interventions and why its effects emerge gradually over weeks of sustained use rather than acutely.
Mitophagy induction — the core mechanism: Mitophagy is the process by which cells selectively target damaged or dysfunctional mitochondria for autophagic degradation, preserving the overall quality of the mitochondrial population and making room for new, healthy mitochondria from biogenesis. The canonical mitophagy pathway involves PINK1 (PTEN-induced kinase 1) accumulation on damaged mitochondria, recruitment of the E3 ubiquitin ligase Parkin, ubiquitination of outer mitochondrial membrane proteins, recognition by autophagy receptors (optineurin, NDP52, p62), formation of autophagosomes around the targeted mitochondria, and fusion with lysosomes for degradation. Several non-canonical mitophagy pathways (BNIP3/NIX, FUNDC1, Bcl2-L-13) operate in parallel, particularly in specialized contexts like erythropoiesis and hypoxic stress. Urolithin A induces mitophagy through mechanisms that include both canonical PINK1/Parkin signaling enhancement and activation of alternative mitophagy pathways, with effects documented in multiple cell types and tissues. Mechanistic studies (Luan et al. 2021; D'Amico et al. 2021) have characterized urolithin A's effects on mitophagy receptor expression, autophagosome formation, and mitochondrial membrane potential sensitivity. The net functional consequence is accelerated clearance of damaged mitochondria, resulting in a fitter overall mitochondrial pool in tissues with high urolithin A exposure.
Supporting mitochondrial biogenesis: While urolithin A's primary mechanism is enhanced clearance of damaged mitochondria, several studies also document effects on mitochondrial biogenesis — the process of creating new mitochondria from existing ones. Urolithin A treatment increases expression of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis, as well as downstream targets including NRF1, NRF2 (nuclear respiratory factors; not the same as the antioxidant Nrf2/Nfe2l2), TFAM (mitochondrial transcription factor A), and nuclear-encoded mitochondrial genes. The combined effect — enhanced clearance of damaged mitochondria plus enhanced generation of new ones — creates net mitochondrial rejuvenation rather than simple reduction or simple expansion. Whether the biogenesis effect is a direct consequence of urolithin A action or an indirect consequence of improved mitochondrial quality (with associated feedback signaling) is not completely resolved.
Skeletal muscle effects: Skeletal muscle is a particularly responsive tissue for urolithin A action, reflecting both its high mitochondrial density and its central role in age-related functional decline (sarcopenia). In muscle, urolithin A treatment improves respiratory function (oxygen consumption rates, respiratory control ratios), reduces markers of mitochondrial dysfunction (damaged mtDNA, altered cristae morphology), improves mitochondrial membrane potential stability, and enhances muscle performance measures. Human clinical trials have documented these muscle-relevant effects in middle-aged and older adults, with functional improvements in muscle strength, endurance, and mitochondrial function parameters. The skeletal muscle responsiveness is clinically relevant because sarcopenia is one of the most consequential aspects of age-related decline, associated with falls, disability, loss of independence, and mortality risk.
Cardiovascular effects: Preclinical data suggest urolithin A may benefit cardiac function by improving cardiomyocyte mitochondrial quality, reducing oxidative stress, and providing ischemic protection. Human cardiovascular outcome data remain limited but initial signals are favorable. The heart's extraordinary mitochondrial density (approximately 30-40 percent of cardiomyocyte volume) makes it another tissue particularly relevant for mitochondrial interventions.
Neurologic effects: Urolithin A crosses the blood-brain barrier and accumulates in neural tissue, where it induces mitophagy in neurons and glial cells. In preclinical models of Alzheimer's disease, urolithin A reduces amyloid accumulation, preserves synaptic function, and improves cognitive performance. Specific neurologic effects include modulation of BDNF signaling, reduced neuroinflammation (microglial activation), and protection against oxidative stress. Human neurologic outcome data are not yet definitive, but mechanistic support for cognitive applications is substantial.
Cellular stress resistance: Beyond the specific mitophagy effect, urolithin A confers resistance to multiple forms of cellular stress including oxidative stress, proteotoxic stress (protein aggregation), and inflammatory stress. These effects likely reflect the contribution of healthy mitochondria to overall cellular homeostasis, combined with direct effects on stress-response pathways like HSP70 expression and Nrf2-mediated antioxidant programs. The broad stress resistance contributes to the general longevity-relevant profile of the compound.
Gut microbiome interactions: Interestingly, urolithin A modulates gut microbiome composition and barrier function. Some studies suggest beneficial effects on gut barrier integrity and reductions in markers of intestinal inflammation, possibly contributing to the compound's anti-inflammaging effects. This microbiome-relevant activity adds another dimension to the urolithin A mechanism profile, though the quantitative significance is unclear.
Anti-inflammatory effects: Urolithin A reduces markers of chronic low-grade inflammation ("inflammaging") in preclinical and clinical studies. Mechanisms include direct effects on NF-κB signaling, modulation of inflammasome activation, reduced ROS-driven inflammation (through improved mitochondrial function), and effects on immune cell mitochondrial health (immune cells have high mitochondrial dependence). These anti-inflammatory effects are less potent than those of dedicated anti-inflammatory polyphenols like curcumin but contribute to the compound's broader metabolic-health profile.
Insulin sensitivity and metabolic effects: Preclinical data suggest urolithin A may improve insulin sensitivity, glucose tolerance, and lipid metabolism, likely mediated through improved mitochondrial function in insulin-responsive tissues (muscle, liver, adipose). Human metabolic outcome data are limited but initial signals are consistent.
Pharmacokinetics: Urolithin A has moderate oral bioavailability after dietary or supplemental intake, with substantial inter-individual variability. Plasma half-life is approximately 8-12 hours, supporting once-daily dosing. Extensive first-pass metabolism produces urolithin A glucuronide and sulfate conjugates (the predominant circulating forms in plasma), which retain biological activity and are further metabolized by tissue enzymes. Tissue distribution includes muscle, liver, kidney, brain, and other tissues. Elimination is primarily through renal excretion of conjugates. Food effects on absorption are modest; urolithin A is generally taken with meals for convenience and to support the moderate lipophilic character of the compound.
Dose-response considerations: Published clinical trials have used doses ranging from 250 mg to 1,000 mg daily, with statistically significant biomarker and functional effects at doses of 500 mg and above. The dose-response relationship is not fully mapped, and some studies suggest that 500 mg produces similar effects to 1,000 mg, while others suggest incremental benefits at higher doses. Most consumer protocols settle in the 500-1,000 mg daily range.
What urolithin A does not do: Urolithin A does not directly supply NAD+ precursor (that's NMN). It does not provide electron transport chain cofactor (that's CoQ10). It does not stabilize cardiolipin (that's SS-31). It does not replace exercise, which remains the most potent overall mitochondrial intervention. Understanding these mechanistic boundaries clarifies why urolithin A complements rather than substitutes for these other interventions in a complete mitochondrial stack.
Overview
Urolithin A (3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one; trade name Mitopure from Timeline Nutrition, formerly Amazentis) is a gut-microbiome-derived metabolite of dietary ellagitannins — polyphenolic compounds found in pomegranates, walnuts, strawberries, raspberries, and several other berries. Unlike most dietary polyphenols, ellagitannins themselves are poorly absorbed from the intestine; their health-relevant bioactivity depends on conversion by specific gut bacteria (primarily Gordonibacter species, along with some Lactobacillus and Bifidobacterium strains) into a family of smaller metabolites called urolithins, of which urolithin A is the most biologically active. This microbial conversion is not universal — published surveys suggest only 30-40 percent of Western adults harbor the gut bacteria necessary to produce meaningful urolithin A from dietary ellagitannin consumption, with the remaining majority producing mainly urolithin B, urolithin C, or minimal urolithin production at all. The conversion capacity ("metabotype") depends on gut microbiome composition shaped by diet, antibiotic history, age, and unknown factors. Direct urolithin A supplementation bypasses the microbiome-dependent conversion step, providing consistent bioactive exposure regardless of individual metabotype.
The scientific story of urolithin A as a longevity-relevant molecule begins with a landmark 2016 paper by Ryu and colleagues at EPFL (École Polytechnique Fédérale de Lausanne) in Switzerland and the biotechnology company Amazentis, published in Nature Medicine (Ryu et al. 2016). The authors screened a library of microbial metabolites for mitochondrial activity and identified urolithin A as a potent inducer of mitophagy — the selective autophagic degradation of damaged mitochondria — in both Caenorhabditis elegans and aged mice. Urolithin A extended lifespan in C. elegans, improved muscle function in aged mice, and reduced markers of mitochondrial dysfunction. Mitophagy, the specific form of autophagy that targets mitochondria for degradation, had by then emerged as a central process in mitochondrial quality control: damaged mitochondria that accumulate with age are normally targeted for degradation via PINK1/Parkin and related pathways, but this mitophagy machinery itself declines with age, producing a vicious cycle of mitochondrial damage accumulation. Urolithin A's demonstrated ability to induce mitophagy even in aged systems made it an attractive candidate for clinical translation.
Timeline (formerly Amazentis) developed and commercialized urolithin A as Mitopure, with pharmaceutical-grade material supported by human clinical trials demonstrating safety, bioavailability, and biomarker effects on mitochondrial function. Phase 1 (Andreux et al. 2019) established safety at doses up to 1,000 mg daily and measured biomarker changes in skeletal muscle. Phase 2 trials (Liu et al. 2022 and Singh et al. 2022) demonstrated improvements in muscle function and mitochondrial biomarkers in middle-aged and older adults. A series of biomarker and mechanistic studies confirmed induction of mitophagy in human tissues following urolithin A administration. Current commercial products are based on this evidence foundation and include Mitopure capsules and softgels, along with various third-party urolithin A products of variable quality. Unlike many longevity compounds that remain investigational or available only through unregulated suppliers, urolithin A has achieved GRAS (Generally Recognized as Safe) status in the United States for several commercial forms, allowing mainstream supplement distribution.
Mechanistically, urolithin A addresses a specific, important, and previously underaddressed aspect of aging: mitochondrial quality control through selective turnover of damaged mitochondria. Aging tissues accumulate dysfunctional mitochondria with reduced respiratory capacity, increased ROS production, damaged membranes, and impaired calcium handling. Removing these damaged organelles is a prerequisite for replacing them with functional ones through mitochondrial biogenesis. If the mitophagy machinery is slow or insufficient, damaged mitochondria accumulate even in the presence of adequate biogenesis signals. Urolithin A accelerates this turnover, functionally "rejuvenating" the mitochondrial population by favoring the retention of healthy organelles and the removal of damaged ones. This mechanism is complementary to and distinct from the effects of other mitochondrial interventions: SS-31 stabilizes mitochondrial membranes to preserve existing mitochondrial function; NMN elevates NAD+ to support mitochondrial biochemistry; CoQ10 provides electron transport chain cofactor; exercise induces both biogenesis and mitophagy. Urolithin A specifically enhances the quality control step that complements these other interventions, and a complete mitochondrial longevity approach often incorporates multiple mechanisms working together.
Practical considerations for urolithin A use are favorable relative to most longevity interventions. Oral bioavailability is moderate (published pharmacokinetic data show meaningful plasma and tissue exposure after oral dosing), eliminating the need for injections required by peptides like SS-31 or MOTS-c. Cost is moderate — commercial Mitopure products run $40-80 monthly at standard doses, while generic urolithin A from reputable supplement companies runs $20-40 monthly. Safety profile is excellent, with clinical trials reporting good tolerability and commercial post-market experience showing minimal concerns. Dosing is straightforward (once daily with food), and timing does not require specialized scheduling. These practical advantages make urolithin A one of the more accessible serious mitochondrial interventions available to consumers, appropriate for users ranging from cautious beginners to advanced longevity practitioners.
Users should calibrate expectations appropriately. Published clinical trials show real but modest effects on mitochondrial biomarkers and muscle function in middle-aged and older adults, with effect sizes in the range typical for other longevity interventions rather than dramatic transformation. The most relevant applications appear to be age-related muscle function decline (sarcopenia prevention), general mitochondrial health support, and complementary coverage within a broader mitochondrial stack. Urolithin A does not cure age-related decline, does not substitute for exercise (which remains the most potent mitochondrial biogenesis stimulus available), and does not address aspects of aging outside mitochondrial quality control. It is best viewed as one useful tool among several for mitochondrial health, with specific advantages in addressing mitophagy that most other interventions do not cover directly.
The microbiome dimension of urolithin A raises interesting questions for users. Some individuals are natural "high converters" who produce urolithin A endogenously from dietary ellagitannins; these individuals may have lower marginal benefit from direct supplementation. Most Western adults are non-converters or low converters who produce little or no urolithin A from pomegranate and walnut consumption; for these individuals, direct supplementation provides access to a bioactive that would otherwise be unavailable from diet. Commercial urinalysis tests can identify urolithin metabotype, though most users skip this step and simply supplement directly based on the reasonable assumption that they are probably not a high converter. Diet continues to matter: even with supplementation, consumption of pomegranate, walnuts, berries, and other ellagitannin sources supports broader polyphenol intake and related health benefits, and the small fraction of users who are high converters produce endogenous urolithin A from these foods.
Positioning urolithin A within a longevity strategy: it integrates naturally with exercise (the fundamental mitochondrial intervention), a solid mitochondrial supplement foundation (CoQ10, NMN, creatine, omega-3), and other complementary interventions as budget and goals allow. For many users, urolithin A offers a meaningful quality-of-life and functional-capacity signal with favorable cost, convenience, and safety — making it one of the more defensible additions to a longevity stack compared to higher-cost or higher-risk experimental options.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Urolithin A has a favorable contraindication profile compared to most longevity interventions. Absolute contraindications are limited; relative contraindications warrant physician input in specific situations. Overall, urolithin A is one of the safer entries in the longevity supplement space.
Pregnancy: Urolithin A supplementation is not recommended during pregnancy. Dietary exposure from ellagitannin-containing foods is safe by long history, and endogenous urolithin production occurs in pregnant women who are natural converters. However, concentrated supplemental dosing during pregnancy has not been adequately studied, and the precautionary principle argues for avoidance. Women of reproductive potential who become pregnant while supplementing should typically discontinue.
Lactation: Urolithin A supplementation is not recommended during breastfeeding. Whether the compound transfers into breast milk in meaningful quantities is not established. Dietary exposure from fruits is acceptable; supplemental dosing is avoided in the absence of specific safety data.
Pediatric use: Urolithin A supplementation is not recommended for children under 18. No pediatric safety or dosing data exist outside research contexts. Dietary ellagitannin intake through fruits is obviously safe and appropriate for children.
Active cancer: Patients with active malignancy should discuss urolithin A supplementation with their oncologist before starting. Preclinical data suggest urolithin A may have anti-cancer effects in some contexts, but effects on established cancers receiving active treatment are context-dependent and potentially variable. Most oncologists prefer to avoid adding supplemental bioactive compounds during active treatment unless part of a specific research protocol. Cancer in remission may allow use but still warrants oncology discussion.
Primary mitochondrial disease: Patients with primary mitochondrial diseases should discuss urolithin A with their mitochondrial specialist. The compound's mitophagy-inducing mechanism is mechanistically interesting for many mitochondrial conditions, but specific disease contexts may have individualized considerations. Effects on mtDNA heteroplasmy (theoretical shifts in the ratio of mutant to wild-type mitochondrial DNA) could be beneficial or detrimental depending on disease and tissue context; this is a theoretical rather than documented concern, but warrants specialist input.
Active hepatic or renal disease: Urolithin A pharmacokinetics in severe hepatic or renal impairment have not been extensively characterized. Users with well-compensated chronic liver or kidney disease may reasonably use urolithin A at standard doses; those with severe or decompensated disease should consult their physician and approach with caution.
Known allergy: Rare allergic reactions to urolithin A or to excipients in specific products have been reported. Users with documented allergies to specific ingredients in commercial products (gelatin, soy, specific oils in softgels) should check formulations and switch products if needed.
Anticoagulant therapy: Urolithin A has minimal antiplatelet activity compared to many polyphenols. Specific interactions with anticoagulants (warfarin, DOACs) or antiplatelet agents (aspirin, clopidogrel) are unlikely to be clinically significant, but users on these medications should discuss new supplement additions with their prescribing physician as general practice.
Surgery and perioperative: Most protocols recommend discontinuing urolithin A 1-2 weeks before major elective surgery as part of general supplement discontinuation guidance. Specific urolithin A perioperative data are not available, so the recommendation is conservative. Resume after recovery.
Autoimmune disease: Urolithin A's immunomodulatory effects are incompletely characterized. Users with active autoimmune disease on immunomodulator therapy should discuss with their rheumatologist. No specific interactions have been documented, but individualized review is appropriate for users on complex immunomodulatory regimens.
Active investigational research: Users participating in clinical trials should disclose all supplements to trial investigators; most protocols prohibit concurrent supplementation that could confound results.
Specific medication considerations: Urolithin A has minimal documented pharmacokinetic interactions, with limited effects on CYP450 enzymes at typical supplement doses. Users on narrow-therapeutic-index drugs should still discuss with their pharmacist or physician, but urolithin A-specific interaction concerns are minimal.
Individual sensitivities: A small percentage of users may have idiosyncratic responses (persistent GI effects, unexplained fatigue, rash). These users should discontinue and consider alternative mitochondrial support strategies.
Cost considerations as "contraindication": While not a medical contraindication, users with limited financial resources should honestly evaluate whether ongoing urolithin A cost fits within their budget. Foundational health behaviors (exercise, sleep, nutrition) produce greater benefit than any supplement and are not affected by financial constraints.
Over-reliance concern: Urolithin A should supplement, not substitute, foundational health behaviors. Users who view urolithin A as a "magic pill" substitute for exercise or sleep will be disappointed and may fail to pursue more impactful interventions. This is a framing concern rather than a medical contraindication.
When physician consultation is appropriate before starting urolithin A: Users with 3 or more chronic prescription medications, users with complex chronic disease, users with active or historical cancer, users on immunomodulators, users with advanced organ dysfunction, users in active clinical research, women planning pregnancy or breastfeeding. For most otherwise-healthy adults, urolithin A can be started without specific medical clearance, though periodic physician wellness visits remain good practice.
Summary contraindication position: Urolithin A is among the safer longevity interventions available, with no absolute contraindications in otherwise-healthy adults and limited relative contraindications in specific populations. The favorable safety profile, GRAS status, and mainstream availability make urolithin A appropriate for broad mainstream use, with ordinary attention to individual circumstances and physician consultation when specific concerns apply.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Urolithin A.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Urolithin A
Research Score
7 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Limited research available
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is urolithin A and where does it come from?
Urolithin A is a metabolite produced by gut bacteria from ellagitannins — polyphenolic compounds found in pomegranates, walnuts, strawberries, raspberries, and some other fruits. When you eat ellagitannin-containing foods, the compounds themselves are poorly absorbed. Instead, specific gut bacteria (primarily Gordonibacter species) convert ellagitannins into urolithins, of which urolithin A is the most biologically active. Critically, only about 30-40 percent of Western adults harbor the right gut bacteria to produce meaningful urolithin A from dietary sources — the rest produce mainly urolithin B, urolithin C, or minimal urolithin production at all. This 'metabotype' depends on gut microbiome composition influenced by diet, antibiotics, age, and unknown factors. Direct urolithin A supplementation bypasses this microbiome-dependent step, providing consistent bioactive exposure regardless of individual conversion capacity. The scientific interest in urolithin A intensified after the 2016 Nature Medicine paper by Ryu and colleagues (PMID 27454312) identified it as a potent inducer of mitophagy — the selective degradation of damaged mitochondria. This discovery, along with subsequent clinical development by Amazentis/Timeline Nutrition (Mitopure), established urolithin A as one of the best-supported longevity-relevant compounds with human clinical trial evidence.
What does urolithin A do, and what is mitophagy?
Urolithin A's primary mechanism is inducing mitophagy — the selective autophagic degradation of damaged mitochondria. Mitochondria are the cellular organelles responsible for energy production, calcium handling, apoptosis regulation, and many other essential functions. Over time, mitochondria accumulate damage — altered membranes, reduced respiratory capacity, increased reactive oxygen species production, damaged mtDNA. Cells have specific machinery (primarily the PINK1/Parkin pathway and related systems) to identify damaged mitochondria and target them for autophagic degradation, making room for replacement with new healthy mitochondria from biogenesis. This mitophagy machinery itself declines with age, producing a vicious cycle where damaged mitochondria accumulate faster than they are cleared. Urolithin A enhances mitophagy induction, accelerating clearance of damaged mitochondria and favoring retention of healthy ones. The functional result is a fitter overall mitochondrial population, better mitochondrial respiratory capacity, reduced ROS production, and improved cellular function — particularly in tissues with high mitochondrial density like muscle and heart. This is distinct from and complementary to the effects of SS-31 (stabilizes existing mitochondrial membranes), NMN (supplies NAD+ for mitochondrial biochemistry), and CoQ10 (electron transport chain cofactor). A comprehensive mitochondrial stack typically includes urolithin A for quality control alongside these other mechanisms.
What clinical evidence supports urolithin A for health and longevity?
Urolithin A has a relatively strong clinical evidence base compared to many longevity compounds. The foundational preclinical paper by Ryu et al. 2016 (PMID 27454312) in Nature Medicine established mitophagy induction, C. elegans lifespan extension, and improved mouse muscle function. Phase 1 human safety by Andreux et al. 2019 (PMID 31477902) established acceptable tolerability at doses up to 2000 mg daily and documented biomarker changes consistent with mitophagy in human skeletal muscle. Phase 2 efficacy trials have demonstrated improved muscle function and mitochondrial biomarkers in middle-aged and older adults: Liu et al. 2022 (PMID 36345188) showed improvements in muscle strength and endurance with 1000 mg daily for 4 months; Singh et al. 2022 (PMID 35732821) characterized metabotype-related benefits and functional effects. Additional trials and ongoing studies continue to build the evidence base. The compound has received GRAS (Generally Recognized as Safe) status in the United States. Honest framing: effect sizes in clinical trials are modest but biologically meaningful, consistent with most longevity interventions; dramatic transformative effects are not expected and should not be expected. Urolithin A is one of the better-supported longevity-relevant compounds with human evidence, not a miracle intervention.
What dose of urolithin A should I take?
The clinical trial dose range is 250-1000 mg daily, with 500-1000 mg representing the sweet spot for most users. Andreux 2019 examined doses up to 2000 mg safely, but benefit appears to plateau around 500-1000 mg. For new users, starting at 250-500 mg daily for the first 1-2 weeks provides gradual introduction and tolerability assessment; transition to 500-1000 mg thereafter. For most adults pursuing mitochondrial health support, 500 mg daily is a reasonable steady-state dose. For users with specific goals (sarcopenia concerns, athletic recovery, age-related decline in middle-aged and older adults), 1000 mg daily aligns with Phase 2 clinical trial dosing and may produce more noticeable effects. Advanced users may use 1000-1500 mg daily. Take once daily with a meal containing some fat (for better absorption) at a consistent time (morning commonly preferred). Split dosing (500 mg twice daily, for example) is acceptable if preferred. The compound's 8-12 hour plasma half-life supports once-daily dosing adequately. Continuous daily use is the standard pattern; cycling is not biologically required but acceptable for cost management or personal preference. Adjust based on subjective response and budget considerations — benefits should emerge subtly over weeks to months.
Is urolithin A safe, and what are the side effects?
Urolithin A has an exceptionally favorable safety profile. It is a naturally occurring metabolite present in human bloodstream from ellagitannin-containing foods, has been studied in multiple clinical trials at doses up to 2000 mg daily without dose-limiting toxicities, has received GRAS (Generally Recognized as Safe) status in the United States, and has extensive post-market consumer experience without emerging safety concerns. The most commonly reported effects are mild gastrointestinal symptoms (occasional abdominal discomfort, bloating, or changes in bowel habits) in a minority of users. These effects are typically mild, transient, and reduced by taking the supplement with food. Rare reports of headache, fatigue during initial weeks, or skin reactions. Laboratory parameters (blood counts, metabolic panels, liver and kidney function) have remained stable in clinical trials. Drug interactions are minimal — urolithin A does not significantly affect CYP450 enzymes or major drug-metabolizing pathways. Theoretical long-term concerns have not materialized in available data. Users should still exercise appropriate caution: discontinue for any severe or persistent symptoms, discuss with physician if on complex medication regimens, avoid during pregnancy and lactation, consult oncology if active cancer. For most otherwise-healthy adults, urolithin A is among the safer longevity interventions available.
Can I get enough urolithin A from eating pomegranates and walnuts?
For most people, no — and this is why direct supplementation is meaningful. Pomegranates, walnuts, and other ellagitannin-containing foods provide substrate for urolithin A production, but actual urolithin A generation depends on gut microbiome composition. Published research suggests only about 30-40 percent of Western adults harbor the gut bacteria (primarily Gordonibacter species) necessary to produce meaningful urolithin A from dietary ellagitannins. The majority of adults are 'non-converters' or 'low converters' who produce little urolithin A from these foods, instead producing other urolithin variants or minimal urolithin at all. This metabotype depends on factors including overall microbiome composition, dietary pattern, antibiotic history, age, and other factors. Commercial urine or stool tests can identify individual urolithin metabotype, though most users skip this step and supplement directly based on the reasonable assumption they probably aren't a high converter. Direct urolithin A supplementation provides consistent bioactive exposure regardless of metabotype. Continued consumption of pomegranates, walnuts, and berries remains beneficial for broader polyphenol intake and general nutrition, and supports endogenous urolithin production in high converters, but does not substitute for supplementation in non-converters who want urolithin A exposure.
How is urolithin A different from NMN, CoQ10, and SS-31?
Urolithin A, NMN, CoQ10, and SS-31 all support mitochondrial health through distinct mechanisms — they are complementary rather than redundant. Urolithin A induces mitophagy, the selective degradation of damaged mitochondria, clearing low-quality organelles to make room for replacement through biogenesis. NMN (and nicotinamide riboside) elevate cellular NAD+, which supports sirtuin activity, mitochondrial biochemistry (as a substrate and signaling molecule), and DNA repair. CoQ10 (as ubiquinol) is an essential electron transport chain cofactor and mitochondrial antioxidant, supporting the function of existing mitochondria. SS-31 (elamipretide) binds cardiolipin on the inner mitochondrial membrane and stabilizes the supramolecular organization of the respiratory chain, preserving the structural integrity of existing mitochondria. A comprehensive mitochondrial stack typically includes multiple mechanisms: urolithin A for quality control, NMN for cofactor supply, CoQ10 for electron transport, and (for advanced protocols) SS-31 for membrane stability. Creatine provides energy buffering. Omega-3 supports membrane composition. Exercise drives biogenesis. No single intervention covers all these aspects; combining them provides broader mitochondrial support than any alone. For foundational use, urolithin A + NMN + CoQ10 + creatine + omega-3 represents a solid core stack. Adding SS-31 or other peptides represents more advanced, higher-cost additions.
Will I feel different when taking urolithin A?
Most users do not experience dramatic acute effects from urolithin A. The compound works through gradual tissue-level changes — accelerated turnover of damaged mitochondria, improved respiratory capacity, enhanced muscle function — that emerge over weeks to months rather than through acute subjective sensations. Some users report subtle improvements after 4-12 weeks of consistent use: better exercise recovery (less post-workout soreness, faster return to baseline), modestly improved muscle performance or endurance, subtle energy improvements during daily activities, possibly somewhat better sleep quality. These effects are typically subtle, variable between individuals, and difficult to distinguish from placebo response without objective measurement. Users expecting dramatic transformation will be disappointed; this is true for most longevity interventions, not just urolithin A. The rational framing is: urolithin A contributes a small favorable effect to mitochondrial health over time, as one element of a broader healthy lifestyle. If you track objective measures (fitness metrics, biomarkers) alongside subjective ones, you may detect effects more reliably. If you perceive clear benefit after 3-6 months, continuation makes sense. If you perceive no benefit and cost is a concern, discontinuation is reasonable — urolithin A is not essential for health, merely supportive.
Should I take Mitopure or generic urolithin A?
Mitopure (Timeline Nutrition's commercial urolithin A product) is the premium option with the strongest direct clinical evidence — it was used in the pivotal clinical trials that established urolithin A's efficacy, and its bioavailability and purity are documented. Mitopure typically costs $40-80 monthly depending on dose and subscription arrangement. Generic urolithin A from reputable supplement brands (companies with third-party testing, established industry track records, published certificates of analysis) typically costs $20-40 monthly at equivalent doses. For most users, generic urolithin A from a quality supplement brand is a reasonable cost-conscious alternative to Mitopure, providing similar active ingredient at lower cost. The tradeoff: direct clinical evidence is for Mitopure specifically; generic products are presumed to provide equivalent urolithin A but lack product-specific validation. Signs of quality generic urolithin A: brand has established track record, published COA from third-party testing, reasonable (not extremely low) pricing, clear sourcing. Signs of concerning generic products: unusually low price, obscure brand, no COA available, exaggerated marketing claims. For users with budget constraints, starting with generic urolithin A from a reputable brand is reasonable; upgrading to Mitopure for comparison if budget allows can inform individual choice. For users with fewer budget constraints and preference for directly evidence-validated product, Mitopure is the stronger choice. Either option captures most of the urolithin A benefit for most users.
How does urolithin A compare to exercise and caloric restriction for mitochondrial health?
Exercise is the most potent mitochondrial intervention available, and no supplement — including urolithin A — substitutes for it. Regular aerobic and resistance exercise drives mitochondrial biogenesis (creating new mitochondria via PGC-1α activation), induces mitophagy (clearing damaged mitochondria through mechanisms overlapping with urolithin A), improves oxidative capacity, enhances substrate availability, and produces adaptations throughout the mitochondrial system. Caloric restriction (including time-restricted eating) also powerfully affects mitochondrial biology through AMPK activation, mTOR inhibition, enhanced autophagy including mitophagy, and metabolic reprogramming. Both exercise and caloric restriction have decades of robust human evidence showing mortality benefits and improved healthy aging. Urolithin A, while mechanistically valid and supported by clinical trial evidence, has effect sizes much smaller than exercise or consistent dietary interventions. The correct framing: prioritize exercise (aim for 150-300 minutes moderate aerobic weekly + resistance training 2-3x weekly), optimize diet (quality whole foods, adequate protein, minimize ultra-processed foods, consider time-restricted eating), and sleep (7-9 hours consistently); add urolithin A as a small incremental support to this foundation. Taking urolithin A instead of exercising is self-defeating; taking it in addition to a solid exercise and nutrition foundation is a reasonable choice for users who want to augment their mitochondrial support. Evidence suggests the combination of exercise plus urolithin A supplementation produces complementary effects, with exercise driving biogenesis and quality control, and urolithin A augmenting the quality control component.
Research Tools
Side-by-Side Comparisons
All ComparisonsCompare Urolithin A head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
